NEULANDLABNSENeuland Laboratories Limited· PharmaceuticalsMinimalNeutral
Announced Tue, 12 May · 19:16 IST

Neuland Laboratories Limited has informed the Exchange regarding a revised press release dated May 12, 2026, titled "Correction in Press Release Header".

NEULANDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.5%1-day move
₹17100.00
prior close
₹18305.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-4.3-4.7-4.7-4.3-2.5-3.5-4.7-2.7-2.7-2.5-1.2-0.2+11.0
Up moveDown movePending
AI summary

Neuland Laboratories has submitted a corrected press release to the stock exchanges following an administrative typographical error in the original filing dated May 12, 2026. The header incorrectly stated "Q4FY26" instead of "FY26" — the document actually covers full-year FY26 results, not quarterly figures. No changes were made to the underlying financial content. FY26 total income stood at Rs. 2,053.1 crore with EBITDA at Rs. 603.4 crore. Q4FY26 also showed exceptional growth with revenue at Rs. 788.7 crore (up 134.9% YoY) and EBITDA at Rs. 319.4 crore (up 448.6% YoY), with EBITDA margins expanding to 40.5%. The correction is purely administrative with no impact on reported figures or business operations.

Likely market impact

No impact on shareholders or stock price — this is a housekeeping filing correcting a typographical error in the press release header. The underlying FY26 financial results remain unchanged.